JP2017532302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532302A5 JP2017532302A5 JP2017512684A JP2017512684A JP2017532302A5 JP 2017532302 A5 JP2017532302 A5 JP 2017532302A5 JP 2017512684 A JP2017512684 A JP 2017512684A JP 2017512684 A JP2017512684 A JP 2017512684A JP 2017532302 A5 JP2017532302 A5 JP 2017532302A5
- Authority
- JP
- Japan
- Prior art keywords
- tev
- utr
- sequence
- human
- gaopt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 108020004705 Codon Proteins 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 102000049953 human LEP Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046487P | 2014-09-05 | 2014-09-05 | |
| US62/046,487 | 2014-09-05 | ||
| PCT/US2015/048535 WO2016037053A1 (en) | 2014-09-05 | 2015-09-04 | Lipids and lipid compositions for the delivery of active agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532302A JP2017532302A (ja) | 2017-11-02 |
| JP2017532302A5 true JP2017532302A5 (https=) | 2018-10-18 |
| JP6731912B2 JP6731912B2 (ja) | 2020-07-29 |
Family
ID=54256820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512684A Active JP6731912B2 (ja) | 2014-09-05 | 2015-09-04 | 活性物質の送達用の脂質および脂質組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10125092B2 (https=) |
| EP (1) | EP3188760B1 (https=) |
| JP (1) | JP6731912B2 (https=) |
| CN (1) | CN107072946B (https=) |
| ES (1) | ES2969956T3 (https=) |
| WO (1) | WO2016037053A1 (https=) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052627B1 (en) | 2013-10-04 | 2018-08-22 | Novartis AG | Novel formats for organic compounds for use in rna interference |
| JP6694811B2 (ja) | 2013-10-04 | 2020-05-20 | ノバルティス アーゲー | ＲＮＡ干渉に使用するためのＲＮＡｉ剤用の３’末端キャップ |
| EP3052107B1 (en) | 2013-10-04 | 2018-05-02 | Novartis AG | Organic compounds to treat hepatitis b virus |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| US10125092B2 (en) * | 2014-09-05 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| KR102630720B1 (ko) | 2015-08-28 | 2024-01-29 | 세키스이 메디칼 가부시키가이샤 | 벤질 화합물 |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| TWI773666B (zh) * | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| US10967057B2 (en) | 2016-06-02 | 2021-04-06 | Glaxosmithkline Biologicals S.A. | Zika viral antigen constructs |
| WO2018029586A1 (en) | 2016-08-07 | 2018-02-15 | Novartis Ag | Mrna-mediated immunization methods |
| EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| BE1025121B1 (fr) | 2016-11-17 | 2018-11-05 | Glaxosmithkline Biologicals Sa | Constructions antigeniques du virus zika |
| EP3595713A4 (en) * | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| EP3630076A1 (en) | 2017-05-30 | 2020-04-08 | GlaxoSmithKline Biologicals SA | Methods for manufacturing a liposome encapsulated rna |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019016680A1 (en) | 2017-07-17 | 2019-01-24 | Glaxosmithkline Biologicals Sa | ANTIGEN CONSTRUCTS OF LYSSAVIRUS |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| EP3836963A2 (en) | 2018-08-17 | 2021-06-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions and uses thereof |
| CN109260174B (zh) * | 2018-09-04 | 2021-10-15 | 中山大学 | 一种治疗性蛋白纳米颗粒的高通量制备方法 |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| EP3646854B1 (en) * | 2018-10-30 | 2022-08-03 | PolyPlus Transfection | Compositions for transfecting mrna into a cell and their applications |
| WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| IL314386A (en) | 2018-12-05 | 2024-09-01 | Intellia Therapeutics Inc | amine modified lipids |
| BR112021010611A2 (pt) | 2018-12-14 | 2021-08-24 | Glaxosmithkline Biologicals S.A. | Composições e métodos de vacina de reforço (prime boost) heterólogo |
| DK3934673T3 (da) * | 2019-03-08 | 2026-04-07 | Massachusetts Inst Technology | Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi |
| KR20220035457A (ko) | 2019-07-21 | 2022-03-22 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 치료 바이러스 백신 |
| US12569438B2 (en) | 2019-07-29 | 2026-03-10 | Georgia Tech Research Corporation | Nanomaterials containing constrained lipids and uses thereof |
| US12533318B2 (en) | 2019-08-30 | 2026-01-27 | Glaxosmithkline Biologicals Sa | Jet mixing lipid nanoparticle manufacturing process |
| IL292989A (en) * | 2019-11-15 | 2022-07-01 | Daiichi Sankyo Co Ltd | Nucleic acid lipid particle vaccine enveloping human papillomavirus mrna |
| US12435035B2 (en) | 2020-01-09 | 2025-10-07 | Guide Therapeutics, Llc | Nanomaterials |
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| WO2021209970A1 (en) | 2020-04-16 | 2021-10-21 | Glaxosmithkline Biologicals Sa | Sars cov-2 spike protein construct |
| US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| EP4171629A1 (en) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4267593A2 (en) | 2020-12-23 | 2023-11-01 | GlaxoSmithKline Biologicals SA | Self-amplifying messenger rna |
| KR20230131863A (ko) * | 2021-01-20 | 2023-09-14 | 빔 테라퓨틱스, 인크. | 나노물질 |
| IL303845A (en) | 2021-01-20 | 2023-08-01 | Beam Therapeutics Inc | Nanomaterials include a degradable property |
| EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
| CN113993839B (zh) * | 2021-02-05 | 2024-02-09 | 嘉晨西海(杭州)生物技术有限公司 | 一种可离子化脂质分子、其制备方法及其在制备脂质纳米颗粒中的应用 |
| CN112961065B (zh) * | 2021-02-05 | 2023-03-14 | 嘉晨西海(杭州)生物技术有限公司 | 一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用 |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20240181037A1 (en) | 2021-03-26 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| EP4342993A4 (en) * | 2021-05-19 | 2025-05-28 | Daiichi Sankyo Company, Limited | Hpv infectious disease vaccine |
| JP2024526021A (ja) * | 2021-05-24 | 2024-07-17 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 核酸のための１成分送達系 |
| EP4346894A1 (en) | 2021-05-24 | 2024-04-10 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
| EP4352247A1 (en) | 2021-06-09 | 2024-04-17 | GlaxoSmithKline Biologicals s.a. | Release assay for determining potency of self-amplifying rna drug product and methods for using |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| JP2024534915A (ja) | 2021-09-03 | 2024-09-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 自己増幅性メッセンジャーリボ核酸におけるヌクレオチド塩基の置換 |
| CA3240127A1 (en) * | 2021-12-07 | 2023-06-15 | Zihao Wang | Rna formulations and lipids |
| CN118401547A (zh) * | 2021-12-17 | 2024-07-26 | 嘉晨西海(杭州)生物技术有限公司 | 白细胞介素-12自我复制rna和方法 |
| JP2023130120A (ja) * | 2022-03-07 | 2023-09-20 | スペラファーマ株式会社 | ペプチド合成方法 |
| EP4499607A1 (en) * | 2022-03-25 | 2025-02-05 | Sail Biomedicines, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
| JP2023181989A (ja) * | 2022-06-13 | 2023-12-25 | 上海臻上医薬科技有限公司 | マイクロニードル注射製剤およびその使用 |
| WO2023242817A2 (en) | 2022-06-18 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2 |
| WO2024019936A1 (en) | 2022-07-20 | 2024-01-25 | Beam Therapeutics Inc. | Nanomaterials comprising triols |
| CN119947747A (zh) | 2022-09-26 | 2025-05-06 | 葛兰素史克生物有限公司 | 流感病毒疫苗 |
| WO2024092209A1 (en) * | 2022-10-28 | 2024-05-02 | Advanced Rna Vaccine (Arv) Technologies, Inc. | Vitamin-based lipids and lipid nanoparticles comprising the same |
| WO2024120490A1 (en) * | 2022-12-07 | 2024-06-13 | Immorna (hangzhou) Biotechnology Co., Ltd. | Self-replicating rna vaccines and methods of use |
| WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| WO2024187158A1 (en) * | 2023-03-08 | 2024-09-12 | The Regents Of The University Of California | Benzaldehyde acetal acid-degradable amphiphilic lipid and self-assembling peptides |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| EP4701658A1 (en) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Influenza virus vaccines |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025011529A2 (en) | 2023-07-07 | 2025-01-16 | Shanghai Circode Biomed Co., Ltd. | Circular rna vaccines for seasonal flu and methods of uses |
| CN121752588A (zh) | 2023-08-29 | 2026-03-27 | 上海环码生物医药有限公司 | 编码vegf多肽的环状rna、制剂和使用方法 |
| WO2025067389A1 (en) * | 2023-09-28 | 2025-04-03 | Immorna (hangzhou) Biotechnology Co., Ltd. | Lipid complex nanoparticle for lung-targeted delivery of nucleic acid therapeutic agent |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| CN120227354A (zh) * | 2023-12-29 | 2025-07-01 | 康希诺(上海)生物研发有限公司 | 一种用于递送核酸的脂质纳米颗粒及其制备方法和用途 |
| WO2025199302A1 (en) * | 2024-03-21 | 2025-09-25 | Nitto Denko Corporation | Ph-sensitive cationic lipids, lipid nanoparticles comprising the same and methods of delivering nucleic acids |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025229572A1 (en) | 2024-05-01 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| WO1994013791A1 (en) | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
| EP1195442A3 (en) | 1992-12-04 | 2002-07-31 | Innovir Laboratories, Inc. | Ribozyme amplified diagnostics |
| US5871914A (en) | 1993-06-03 | 1999-02-16 | Intelligene Ltd. | Method for detecting a nucleic acid involving the production of a triggering RNA and transcription amplification |
| JPH09504517A (ja) | 1993-09-27 | 1997-05-06 | スミスクライン・ビーチャム・コーポレイション | カンプトテシン処方物 |
| US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| WO1998027104A1 (en) | 1996-12-19 | 1998-06-25 | Yale University | Bioreactive allosteric polynucleotides |
| US20030036517A1 (en) | 1997-12-05 | 2003-02-20 | Bruce A. Sullenger | Nucleic acid mediated rna tagging and rna revision |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| IL126731A0 (en) | 1998-10-23 | 1999-08-17 | Intelligene Ltd | A method of detection |
| EP1133513A4 (en) | 1998-11-03 | 2002-07-03 | Univ Yale | MULTI-DOMAIN POLYNUCLEOTIDE MOLECULAR DETECTORS |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7112337B2 (en) * | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| WO2002002606A2 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| DK1328543T3 (da) | 2000-10-27 | 2009-11-23 | Novartis Vaccines & Diagnostic | Nukleinsyrer og proteiner fra streptococcus-gruppe A & B |
| JP2005506322A (ja) | 2001-08-31 | 2005-03-03 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種 |
| CN1812809A (zh) | 2003-06-26 | 2006-08-02 | 希龙公司 | 用于沙眼衣原体的免疫原性组合物 |
| JP4875490B2 (ja) | 2003-07-31 | 2012-02-15 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物 |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| US7811602B2 (en) | 2004-05-17 | 2010-10-12 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| NZ599345A (en) | 2005-02-18 | 2013-07-26 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic Escherichia Coli |
| AU2006214064B2 (en) | 2005-02-18 | 2012-04-26 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| CN101687025A (zh) | 2005-03-30 | 2010-03-31 | 诺华疫苗和诊断公司 | B型流感嗜血杆菌 |
| EP1891096A2 (en) | 2005-05-12 | 2008-02-27 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for chlamydia trachomatis |
| ES2615083T3 (es) * | 2005-09-20 | 2017-06-05 | Jitsubo Co., Ltd. | Vehículo de separación, método de separación de un compuesto, y método de síntesis del péptido utilizando el vehículo |
| CA2627302A1 (en) | 2005-10-25 | 2007-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Compositions comprising yersinia pestis antigens |
| WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
| CN101903018B (zh) * | 2007-10-17 | 2012-09-05 | 韩国科学技术院 | 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法 |
| ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
| EP2268659A2 (en) | 2008-03-06 | 2011-01-05 | Novartis AG | Mutant forms of chlamydia htra |
| MX2011010735A (es) | 2009-04-14 | 2012-01-25 | Novartis Ag | Composiciones para inmunizacion contra staphylococcus aureus. |
| US20110300205A1 (en) | 2009-07-06 | 2011-12-08 | Novartis Ag | Self replicating rna molecules and uses thereof |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| JP2014101274A (ja) * | 2011-03-09 | 2014-06-05 | Jitsubo Co Ltd | 新規な架橋構造を含むｔｎｆレセプターループペプチドの模倣ペプチドを用いた医薬組成物 |
| CN103415530A (zh) | 2011-03-09 | 2013-11-27 | Jitsubo株式会社 | 新型的含有非肽性交联结构的交联肽、以及该交联肽的合成方法和用于该方法的新型有机化合物 |
| EP2788006B1 (en) * | 2011-12-07 | 2026-01-07 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| JP6136934B2 (ja) | 2011-12-15 | 2017-05-31 | 味の素株式会社 | Ｆｍｏｃ基の除去方法 |
| US9504747B2 (en) * | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10125092B2 (en) * | 2014-09-05 | 2018-11-13 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3630076A1 (en) * | 2017-05-30 | 2020-04-08 | GlaxoSmithKline Biologicals SA | Methods for manufacturing a liposome encapsulated rna |
| BR112021010611A2 (pt) * | 2018-12-14 | 2021-08-24 | Glaxosmithkline Biologicals S.A. | Composições e métodos de vacina de reforço (prime boost) heterólogo |
-
2015
- 2015-09-04 US US15/505,282 patent/US10125092B2/en active Active
- 2015-09-04 EP EP15775528.1A patent/EP3188760B1/en active Active
- 2015-09-04 JP JP2017512684A patent/JP6731912B2/ja active Active
- 2015-09-04 CN CN201580060043.1A patent/CN107072946B/zh active Active
- 2015-09-04 WO PCT/US2015/048535 patent/WO2016037053A1/en not_active Ceased
- 2015-09-04 ES ES15775528T patent/ES2969956T3/es active Active
-
2018
- 2018-09-19 US US16/135,116 patent/US10844002B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532302A5 (https=) | ||
| JP2017048194A5 (https=) | ||
| JP2019194236A5 (https=) | ||
| JP2018520997A5 (https=) | ||
| JP2018024670A5 (https=) | ||
| JP2010227108A5 (https=) | ||
| JP2017186358A5 (https=) | ||
| JP2020022459A5 (https=) | ||
| JP2011155981A5 (https=) | ||
| JP2017153484A5 (https=) | ||
| WO2017070626A3 (en) | Respiratory virus vaccines | |
| JP2014000092A5 (https=) | ||
| JP2010065037A5 (https=) | ||
| FI3872085T3 (fi) | Esimuotoiset virussekvenssit ja niiden käytöt | |
| JP2017534262A5 (https=) | ||
| JP2016539629A5 (https=) | ||
| JP2018033454A5 (https=) | ||
| JP2010501534A5 (https=) | ||
| EA202190602A3 (ru) | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний | |
| JP2012115277A5 (https=) | ||
| JP2010088434A5 (https=) | ||
| MX2017011386A (es) | NUCLEÓTIDOS DE PURINA ß-D-2'-DEOXI-2'A-FLUORO-2'-ß-C-SUSTITUIDOS-2 - MODIFICADOS-N6- SUSTITUIDOS PARA EL TRATAMIENTO DEL VIRUS DE LA HEPATITIS C. | |
| JP2012505657A5 (https=) | ||
| JP2015199738A5 (https=) | ||
| JP2015128433A5 (https=) |